A review of therapeutic agents for the management of pulmonary arterial hypertension

被引：10

作者：

Hahn, Stella S. ^{[1
]}

Makaryus, Mina ^{[1
]}

Talwar, Arunabh ^{[1
]}

Narasimhan, Mangala ^{[1
]}

Zaidi, Gulrukh ^{[1
]}

机构：

[1] Northwell Hlth, Div Pulm Crit Care & Sleep Med, 410 Lakeville Rd,Suite 107, New Hyde Pk, NY 11042 USA

来源：

THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE | 2017年 / 11卷 / 01期

关键词：

pulmonary arterial hypertension; prostanoid; endothelin receptor antagonist; phosphodiesterase inhibitor; soluble guanylate cyclase stimulator; ENDOTHELIN RECEPTOR ANTAGONIST; RANDOMIZED CONTROLLED-TRIAL; CONTINUOUS INTRAVENOUS EPOPROSTENOL; NITRIC-OXIDE SYNTHASE; 5 INHIBITOR THERAPY; DOUBLE-BLIND; INHALED ILOPROST; ORAL TREPROSTINIL; COMBINATION THERAPY; PROSTACYCLIN ANALOG;

D O I：

10.1177/1753465816665289

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

Pulmonary arterial hypertension (PAH) is an uncommon, progressive and life threatening disease characterized by a proliferative vasculopathy of the small muscular pulmonary arterioles resulting in elevated pulmonary vascular resistance and eventually right ventricular failure. An increasing understanding of the pathobiology of PAH and its natural history has led to the development of numerous targeted therapies. Despite these advances there is significant progression of disease and the survival rate remains low. This article reviews the agents currently available for the medical management of PAH.

引用

页码：46 / 63

页数：18

共 50 条

[21] New pharmacotherapy options for pulmonary arterial hypertension
Perrin, Swanny
Chaumais, Marie-Camille
O'Connell, Caroline
Amar, David
Savale, Laurent
Jais, Xavier
Montani, David
Humbert, Marc
Simonneau, Gerald
Sitbon, Olivier
[J]. EXPERT OPINION ON PHARMACOTHERAPY, 2015, 16 (14) : 2113 - 2131
[22] An Update on Medical Therapy for Pulmonary Arterial Hypertension
Wu, Yan
O'Callaghan, Dermot S.
Humbert, Marc
[J]. CURRENT HYPERTENSION REPORTS, 2013, 15 (06) : 614 - 622
[23] Existing Drugs and Agents Under Investigation for Pulmonary Arterial Hypertension
Sharma, Mala
Pinnamaneni, Sowmya
Aronow, Wilbert S.
Jozwik, Bartosz
Frishman, William H.
[J]. CARDIOLOGY IN REVIEW, 2014, 22 (06) : 297 - 305
[24] Treatment of pulmonary arterial hypertension
Sitbon, Olivier
Savale, Laurent
Jais, Xavier
Montani, David
Humbert, Marc
Simonneau, Gerald
[J]. PRESSE MEDICALE, 2014, 43 (09): : 981 - 993
[25] Prostacyclin for pulmonary arterial hypertension
Barnes, Hayley
Yeoh, Hui-Ling
Fothergill, Toby
Burns, Andrew
Humbert, Marc
Williams, Trevor
[J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2019, (05):
[26] Treatment of pulmonary arterial hypertension
Roman, Antonio
Lopez-Meseguer, Manuel
Domingo, Enric
[J]. MEDICINA CLINICA, 2015, 144 (12): : 566 - 570
[27] Adverse Events of Prostacyclin Mimetics in Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis
Picken, Christina
Fragkos, Konstantinos C.
Eddama, Mohammad
Coghlan, Gerry
Clapp, Lucie H.
[J]. JOURNAL OF CLINICAL MEDICINE, 2019, 8 (04)
[28] New Therapeutic Paradigms and Guidelines in the Management of Pulmonary Arterial Hypertension
Hill, Nicholas S.
Cawley, Michael J.
Heggen-Peay, Cherilyn L.
[J]. JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2016, 22 (03) : S3 - S19
[29] Safety and tolerability of bosentan in the management of pulmonary arterial hypertension
Roberts, Kari E.
Preston, Ioana R.
[J]. DRUG DESIGN DEVELOPMENT AND THERAPY, 2009, 3 : 111 - 118
[30] Risk stratification and medical therapy of pulmonary arterial hypertension
Galie, Nazzareno
Channick, Richard N.
Frantz, Robert P.
Gruenig, Ekkehard
Jing, Zhi Cheng
Moiseeva, Olga
Preston, Ioana R.
Pulido, Tomas
Safdar, Zeenat
Tamura, Yuichi
McLaughlin, Vallerie V.
[J]. EUROPEAN RESPIRATORY JOURNAL, 2019, 53 (01)

← 1 2 3 4 5 →